CONDENSED COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands	Total	Hyperfine Convertible Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Common Stock Class A Common Stock	Common Stock Class B Common Stock
Balance at Dec. 31, 2020	$ (61,054)		$ 10,415	$ (71,469)
Balance (in shares) at Dec. 31, 2020		95,010,858
Balance at Dec. 31, 2020		$ 128,286
Balance (in shares) at Dec. 31, 2020					1,576,137
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,794)			(7,794)
Issuance of Series D convertible preferred stock, net of issuance costs		$ 30,461
Issuance of Series D convertible preferred stock, net of issuance costs (in shares)		14,171,333
Investment from 4Bionics, LLC	700		700
Exercise of stock options	49		49
Exercise of stock options (in shares)					41,958
Stock-based compensation expense	267		267
Balance at Mar. 31, 2021	(67,832)		11,431	(79,263)
Balance (in shares) at Mar. 31, 2021		109,182,191
Balance at Mar. 31, 2021		$ 158,747
Balance (in shares) at Mar. 31, 2021					1,618,095
Balance at Dec. 31, 2021	186,227		322,540	(136,320)	$ 5	$ 2
Balance (in shares) at Dec. 31, 2021					55,277,061	15,055,288
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(23,775)			(23,775)
Stock-based compensation expense	4,111		4,111
Balance at Mar. 31, 2022	$ 166,563		$ 326,651	$ (160,095)	$ 5	$ 2
Balance (in shares) at Mar. 31, 2022					55,277,061	15,055,288